|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00728208 |
This study will consist of 4 parallel cohorts of healthy volunteers(elderly male, elderly female, young male and young female. Subjects will receive either GSK372475 1.5mg or placebo for 28 days
Condition | Intervention | Phase |
Depression |
Drug: GSK372475 |
Phase I |
MedlinePlus related topics: | Depression |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Pharmacokinetics Study |
Official Title: | A Placebo-Controlled, Single-Blind, Randomised, Parallel Group, 28-Day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 in Healthy Young and Elderly, Male and Female Subjects |
Estimated Enrollment: | 66 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany | |||||
GSK Clinical Trials Call Center | Not yet recruiting | ||||
Berlin, Germany, D-14050 | |||||
Contact: GSK Clinical Trials Call Center 1-877-379-3718 |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | 105467 |
First Received: | July 31, 2008 |
Last Updated: | August 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00728208 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|